NewsBenzinga매크로제닉스, 진행성 고형암 환자 대상 비공개 표적 항체-약물 접합체 MGC030의 1상 임상시험에서 첫 환자 투여 매크로제닉스, 진행성 고형암 환자 대상 비공개 표적 항체-약물 접합체 MGC030의 1상 임상시험에서 첫 환자 투여 Benzinga 2026.10.15 20:06 (GMT+0) Open on Benzinga Other news Bored Ape NFTs Enter Solana With 8 Rare Cards Anthropic announces public benefit fund, commits 5% of shares to public interest Broadcom, Verizon among 9 US companies opposing tokenized trading of their stocks on OKXICE Exclusive | Some Wall Street Leaders are Weighing Bailing on ‘Davos in the Desert’ After Attacks on Riyadh Why 1 Analyst Is Cooling Their Stance on Red-Hot DELL Stock Intel vs. AMD: The CPU Comeback Has Become a 2-Stock Fight, But 1 Is the Better Buy
Exclusive | Some Wall Street Leaders are Weighing Bailing on ‘Davos in the Desert’ After Attacks on Riyadh
